FDA Gives Bristol-Myers Squibb's CAR-T Liso-Cel a Priority Review
The Food and Drug Administration is giving a priority review to lisocabtagene maraleucel (liso-cel), a CAR-T (chimeric antigen receptor T-cell) therapy from Bristol-Myers Squibb (NYSE: BMY). The agency plans to make a decision on the marketing application by Aug. 17, four months earlier than it would have under the standard review process.
Like other CAR-T therapies being developed by various biotech companies, liso-cel involves taking immune cells from the patient, manipulating them so they target lymphoma cells that express a specific protein -- in this case, one called CD19 -- and then putting them back into the patient, where they attack the blood cancer.
Image source: Getty Images.
Source Fool.com
